• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Kosmos Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

    8/7/23 8:07:18 AM ET
    $ACGN
    $AGRI
    $BACK
    $BCAN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Metal Fabrications
    Industrials
    Get the next $ACGN alert in real time by email

    Gainers

    • Save Foods, Inc. (NASDAQ:SVFD) shares surged 76.6% to $1.13 in pre-market trading after gaining 15% on Friday.
    • Missfresh Limited (NASDAQ:MF) rose 65.6% to $3.28 in pre-market trading. Missfresh shares jumped around 285% on Friday after the company announced entry of share purchase agreements for financing and business acquisition.
    • AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) shares rose 32.5% to $0.1726 in pre-market trading after gaining around 7% on Friday.
    • BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) gained 28.4% to $1.85 in pre-market trading after gaining over 7% on Friday.
    • Yunji Inc. (NASDAQ:YJ) shares gained 23.8% to $1.25 in pre-market trading after falling over 7% on Friday.
    • Rubicon Technologies, Inc. (NYSE:RBT) shares climbed 17.7% to $1.20 in pre-market trading. Rubicon Technologies is expected to release its second quarter 2023 financial results on Aug. 8, 2023.
    • Eastside Distilling, Inc. (NASDAQ:EAST) rose 14.6% to $3.58 in pre-market trading. Eastside Distilling is expected to report its second quarter financial results on Aug. 14, 2023.
    • T2 Biosystems, Inc. (NASDAQ:TTOO) gained 13.4% to $0.2835 in pre-market trading after falling 28% on Friday.
    • Gatos Silver, Inc. (NYSE:GATO) shares gained 13.1% to $5.52 in pre-market trading. Gatos Silver is expected to release its second quarter 2023 operating and financial results on Aug. 8, 2023.
    • Kosmos Energy Ltd. (NYSE:KOS) shares rose 4.5% to $7.64 in pre-market trading after the company reported results for its second quarter.

    Losers

    • Tivic Health Systems, Inc. (NASDAQ:TIVC) fell 40.3% to $0.0428 in pre-market trading after the company priced $1.4 million public offering of 33.17 million shares at $0.041 per share.
    • Yellow Corporation (NASDAQ:YELL) shares fell 26.6% to $2.62 in pre-market trading after the company said it filed voluntary Chapter 11 petitions.
    • Aceragen, Inc. (NASDAQ:ACGN) fell 24.9% to $0.56 in pre-market trading. Aceragen, intends to voluntarily terminate the listing of its common stock on the Nasdaq Capital Market.
    • Tempo Automation Holdings, Inc. (NASDAQ:TMPO) fell 18.2% to $0.3080 in pre-market trading after jumping around 50% on Friday.
    • HUTCHMED (China) Limited (NYSE:HCM) fell 14.1% to $14.06 in pre-market.
    • IMAC Holdings, Inc. (NASDAQ:BACK) shares fell 12.1% to $0.1015 in pre-market trading.
    • Scilex Holding Company (NASDAQ:SCLX) shares fell 10.1% to $4.81 in pre-market trading after dropping 15% on Friday.
    • Sientra, Inc. (NASDAQ:SIEN) fell 9.9% to $3.01 in pre-market trading. Sientra is expected to release financial results for the second quarter of 2023 on Aug. 10, 2023.
    • ContraFect Corporation (NASDAQ:CFRX) fell 9.1% to $1.01 in pre-market trading. ContraFect entered into warrant exercise transaction for proceeds of $9.6 million.
    • iBio, Inc. (NYSE:IBIO) fell 7.9% to $0.6198 in pre-market trading after jumping 36% on Friday.

     

    Now Read This: Tyson Foods, Henry Schein And 3 Stocks To Watch Heading Into Monday

    Get the next $ACGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACGN
    $AGRI
    $BACK
    $BCAN

    CompanyDatePrice TargetRatingAnalyst
    Kosmos Energy Ltd.
    $KOS
    3/25/2026$4.25Accumulate → Buy
    Johnson Rice
    Kosmos Energy Ltd.
    $KOS
    12/5/2025$3.50Buy → Accumulate
    Johnson Rice
    Kosmos Energy Ltd.
    $KOS
    12/5/2025$1.00Buy → Underperform
    BofA Securities
    Kosmos Energy Ltd.
    $KOS
    11/11/2025$1.75Equal-Weight
    Stephens
    Kosmos Energy Ltd.
    $KOS
    10/24/2025$4.00Buy
    Clarksons Platou
    iBio Inc.
    $IBIO
    10/21/2025$5.00Outperform
    Oppenheimer
    iBio Inc.
    $IBIO
    10/17/2025$2.00Outperform
    Leerink Partners
    Kosmos Energy Ltd.
    $KOS
    9/22/2025$2.00Buy → Neutral
    Goldman
    More analyst ratings

    $ACGN
    $AGRI
    $BACK
    $BCAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Yunji Announces Second Half and Fiscal Year 2025 Unaudited Financial Results

    HANGZHOU, China, March 27, 2026 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ:YJ), a leading membership-based social e-commerce platform, today announced its unaudited financial results for the second half and fiscal year ended December 31, 20251. Second Half 2025 HighlightsTotal revenues in the second half of 2025 were RMB158.7 million (US$22.7 million), compared with RMB183.8 million in the same period of 2024. The change was primarily due to the Company's continued strategy to refine its product selection across all categories and optimize its selection of suppliers and merchants, together with a deliberate scale-back of the marketplace business.Repeat purchase rate2 in th

    3/27/26 6:00:00 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with relapsed/refractory diffuse large B-cell lymphoma ("DLBCL") in China. The first patient received the first dose on March 20, 2026. DLBCL is the most common form of aggressive non-Hodgkin lymphoma ("NHL") worldwide, accounting for approximately 40% of all NHL cases in China.1  In 2022, approximately 81,000 new cases of NHL are estimated to have been diagnosed in China

    3/22/26 8:00:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Yunji to Report Second Half and Fiscal Year 2025 Financial Results on March 27, 2026

    HANGZHOU, China, March 20, 2026 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ:YJ), a leading membership-based social e-commerce platform, today announced that it plans to release its unaudited financial results for the second half and fiscal year ended December 31, 2025, before the market opens on Friday, March 27, 2026. The earnings release will be available on the Company's investor relations website at https://investor.yunjiglobal.com/. The Company will hold a conference call on Friday, March 27, 2026 at 7:30 A.M. Eastern Time or 7:30 P.M. Beijing/Hong Kong Time to discuss its earnings. Listeners may access the call by dialing the following numbers:International:1-412-902-

    3/20/26 7:30:00 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    $ACGN
    $AGRI
    $BACK
    $BCAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ogunlesi Adebayo O. bought $6,000,000 worth of shares (3,157,895 units at $1.90), increasing direct ownership by 174% to 4,974,184 units (SEC Form 4)

    4 - Kosmos Energy Ltd. (0001509991) (Issuer)

    3/12/26 4:45:15 PM ET
    $KOS
    Oil & Gas Production
    Energy

    SVP and CFO Shah Nealesh D. bought $299,999 worth of shares (157,894 units at $1.90), increasing direct ownership by 9% to 1,863,061 units (SEC Form 4)

    4 - Kosmos Energy Ltd. (0001509991) (Issuer)

    3/12/26 4:44:08 PM ET
    $KOS
    Oil & Gas Production
    Energy

    Director Stice J Michael bought $99,999 worth of shares (52,631 units at $1.90), increasing direct ownership by 34% to 207,620 units (SEC Form 4)

    4 - Kosmos Energy Ltd. (0001509991) (Issuer)

    3/12/26 4:44:49 PM ET
    $KOS
    Oil & Gas Production
    Energy

    $ACGN
    $AGRI
    $BACK
    $BCAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kosmos Energy upgraded by Johnson Rice with a new price target

    Johnson Rice upgraded Kosmos Energy from Accumulate to Buy and set a new price target of $4.25

    3/25/26 8:24:14 AM ET
    $KOS
    Oil & Gas Production
    Energy

    Kosmos Energy downgraded by Johnson Rice with a new price target

    Johnson Rice downgraded Kosmos Energy from Buy to Accumulate and set a new price target of $3.50

    12/5/25 8:35:07 AM ET
    $KOS
    Oil & Gas Production
    Energy

    Kosmos Energy downgraded by BofA Securities with a new price target

    BofA Securities downgraded Kosmos Energy from Buy to Underperform and set a new price target of $1.00

    12/5/25 8:34:56 AM ET
    $KOS
    Oil & Gas Production
    Energy

    $ACGN
    $AGRI
    $BACK
    $BCAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Banjak Marc

    4 - iBio, Inc. (0001420720) (Issuer)

    3/27/26 4:05:18 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Li Dan (Nmn)

    3 - Yunji Inc. (0001759614) (Issuer)

    3/27/26 9:06:45 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 4 filed by Duran Felipe

    4 - iBio, Inc. (0001420720) (Issuer)

    3/23/26 7:31:15 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AGRI
    $BACK
    $BCAN
    SEC Filings

    View All

    SEC Form 6-K filed by Yunji Inc.

    6-K - Yunji Inc. (0001759614) (Filer)

    3/27/26 6:37:54 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    Tivic Health Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/25/26 4:25:57 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    3/23/26 6:07:14 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AGRI
    $BACK
    $BCAN
    Financials

    Live finance-specific insights

    View All

    Yunji Announces Second Half and Fiscal Year 2025 Unaudited Financial Results

    HANGZHOU, China, March 27, 2026 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ:YJ), a leading membership-based social e-commerce platform, today announced its unaudited financial results for the second half and fiscal year ended December 31, 20251. Second Half 2025 HighlightsTotal revenues in the second half of 2025 were RMB158.7 million (US$22.7 million), compared with RMB183.8 million in the same period of 2024. The change was primarily due to the Company's continued strategy to refine its product selection across all categories and optimize its selection of suppliers and merchants, together with a deliberate scale-back of the marketplace business.Repeat purchase rate2 in th

    3/27/26 6:00:00 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    Yunji to Report Second Half and Fiscal Year 2025 Financial Results on March 27, 2026

    HANGZHOU, China, March 20, 2026 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ:YJ), a leading membership-based social e-commerce platform, today announced that it plans to release its unaudited financial results for the second half and fiscal year ended December 31, 2025, before the market opens on Friday, March 27, 2026. The earnings release will be available on the Company's investor relations website at https://investor.yunjiglobal.com/. The Company will hold a conference call on Friday, March 27, 2026 at 7:30 A.M. Eastern Time or 7:30 P.M. Beijing/Hong Kong Time to discuss its earnings. Listeners may access the call by dialing the following numbers:International:1-412-902-

    3/20/26 7:30:00 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

    SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio's strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and will include a presentation from Martin Brenner, DVM, Ph.D., iBio's Chief Executive Officer and Chief Scientific Officer, and Cory Schwartz, Ph.D., the Company's Director of Research and Early Development. iBio is engineering a selective bispecific antibo

    3/16/26 4:30:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AGRI
    $BACK
    $BCAN
    Leadership Updates

    Live Leadership Updates

    View All

    Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

    PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company's litigation and intellectual property counsel. Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the C

    1/2/26 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the N

    10/14/25 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AGRI
    $BACK
    $BCAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by iBio Inc.

    SC 13G - iBio, Inc. (0001420720) (Subject)

    11/14/24 8:47:49 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by iBio Inc.

    SC 13G/A - iBio, Inc. (0001420720) (Subject)

    11/14/24 4:48:52 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by T2 Biosystems Inc.

    SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

    11/14/24 3:38:45 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care